Biblio

W. H. Bisson, Amedei, A., Memeo, L., Forte, S., and Felsher, D. W., “Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons”, Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018, pp. 473 - 510.

T. D. Hubbard, Murray, I. A., Bisson, W. H., Lahoti, T. S., Gowda, K., Amin, S. G., Patterson, A. D., and Perdew, G. H., “Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles”, Scientific reports, vol. 5, 2015.

B. C. Goodale, La Du, J. K., Bisson, W. H., Janszen, D. B., Waters, K. M., and Tanguay, R. L., “AHR2 Mutant Reveals Functional Diversity of Aryl Hydrocarbon Receptors in Zebrafish”, PLoS ONE, vol. 7, no. 1, p. e29346, 2012.

B. C. Goodale, La Du, J. K., Bisson, W. H., Janszen, D. B., Waters, K. M., and Tanguay, R. L., “AHR2 mutant reveals functional diversity of aryl hydrocarbon receptors in zebrafish.”, PLoS One, vol. 7, no. 1, p. e29346, 2012.

H. Nian, Bisson, W. H., Dashwood, W. - M., Pinto, J. T., and Dashwood, R. H., “$\alpha$-Keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells”, Carcinogenesis, vol. 30, pp. 1416–1423, 2009.

S. Sengupta, Bisson, W. H., Mathew, L. K., Kolluri, S. K., and Tanguay, R. L., “Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model.”, Comp Biochem Physiol C Toxicol Pharmacol, vol. 156, no. 2, pp. 121-9, 2012.

S. Sengupta, Bisson, W. H., Mathew, L. K., Kolluri, S., and Tanguay, R. L., “Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model”, Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, vol. 156, no. 2, pp. 121 - 129, 2012.

D. C. Koch, Jang, H. S., O'Donnell, E. F., Punj, S., Kopparapu, P. R., Bisson, W. H., Kerkvliet, N. I., and Kolluri, S., “Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1.”, Oncogene, 2015.

E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S. Kumar, “The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor.”, PLoS One, vol. 5, no. 10, 2010.

E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., and Kolluri, S., “The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor”, PLoS ONE, vol. 5, no. 10, p. e13128, 2010.

E. F. O'Donnell, Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R., and , “The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor”, PLoS One, vol. 5, p. e13128, 2010.

E. F. O'Donnell, Koch, D. C., Bisson, W. H., Jang, H. S., and Kolluri, S., “The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells”, Cell death & disease, vol. 5, p. e1038, 2014.

W. H. Goodson, Lowe, L., Carpenter, D. O., Gilbertson, M., Ali, A. Manaf, Salsamendi, A. Lopez de C., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., and Bisson, W. H., “Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead”, Carcinogenesis, vol. 36, pp. S254–S296, 2015.

Z. Hu, Brooks, S. A., Dormoy, V., Hsu, C. - W., Hsu, H. - Y., Lin, L. - T., Massfelder, T., W Rathmell, K., Xia, M., Al-Mulla, F., and Bisson, W. H., “Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis”, Carcinogenesis, vol. 36, pp. S184–S202, 2015.

W. H. Bisson, Zhang, Z., Welsh, K., Huang, J. - W., Ryan, J., Reed, J. C., and Pellecchia, M., “Binding Properties of the C-terminal Domain of VIAF”, Chemical biology & drug design, vol. 72, pp. 331–336, 2008.

S. A. S. Langie, Koppen, G., Desaulniers, D., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Azqueta, A., Bisson, W. H., Brown, D., Brunborg, G., and , “Causes of genome instability: the effect of low dose chemical exposures in modern society”, Carcinogenesis, vol. 36, pp. S61–S88, 2015.

J. Kravchenko, Corsini, E., Williams, M. A., Decker, W., Manjili, M. H., Otsuki, T., Singh, N., Al-Mulla, F., Al-Temaimi, R., Amedei, A., and Bisson, W. H., “Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions”, Carcinogenesis, p. bgv033, 2015.

L. R. Zarour, Anand, S., Billingsley, K. G., Bisson, W. H., Cercek, A., Clarke, M. F., Coussens, L. M., Gast, C. E., Geltzeiler, C. B., Hansen, L., Kelley, K. A., Lopez, C. D., Rana, S. R., Ruhl, R., V Tsikitis, L., Vaccaro, G. M., Wong, M. H., and Mayo, S. C., “Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.”, Cell Mol Gastroenterol Hepatol, vol. 3, no. 2, pp. 163-173, 2017.

H. Kim, Banerjee, N., Ivanov, I., Pfent, C. M., Prudhomme, K. R., Bisson, W. H., Dashwood, R. H., Talcott, S. T., and Mertens-Talcott, S. U., “Comparison of anti-inflammatory mechanisms of mango ( Mangifera Indica L.) and pomegranate ( Punica Granatum L.) in a preclinical model of colitis”, Molecular Nutrition & Food Research, p. n/a - n/a, 2016.

G. G. Sharma, Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., Bidoli, P., Bisson, W. H., Pagni, F., Piazza, R., Gambacorti-Passerini, C., and Mologni, L., “A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib”, Journal of Thoracic Oncology, vol. 14, no. 11, pp. e257 - e259, 2019.

L. Yang, Broderick, D., Campbell, Y., Gombart, A. F., Stevens, J. F., Jiang, Y., Hsu, V. L., Bisson, W. H., and Maier, C. S., “Conformational Modulation of the Farnesoid X Receptor by Prenylflavonoids: Insights from Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), Fluorescence Titration and Molecular Docking Studies.”, Biochim Biophys Acta, 2016.

M. Ceccon, Mologni, L., Bisson, W. H., Scapozza, L., and Gambacorti-Passerini, C., “Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors”, Molecular Cancer Research, vol. 11, pp. 122–132, 2013.

T. Wang, Bisson, W. H., Mäser, P., Scapozza, L., and Picard, D., “Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors”, Journal of medicinal chemistry, vol. 57, pp. 2524–2535, 2014.

S. K. Joshi, Bisson, W. H., Qian, K., Huang, A., Watanabe-Smith, K., Tyner, J. W., Davare, M. Ashok, McWeeney, S. K., Tognon, C. E., and Druker, B. J., “Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in LeukemiaDisclosures”, Blood, vol. 134, no. Supplement_1, pp. 1256 - 1256, 2019.

W. H. Bisson, Cheltsov, A. V., Bruey-Sedano, N., Lin, B., Chen, J., Goldberger, N., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., and , “Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs”, Proceedings of the National Academy of Sciences, vol. 104, pp. 11927–11932, 2007.